Pricing Log in Create free account
Friday 6 November 2026 Export PTCT’s income statement to Excel — free account

PTC Therapeutics, Inc.

PTCT Healthcare Biotechnology

PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.

Revenue
+69.6%
EPS
−409.7%
Free cash flow
+90.3%
Total debt
+19.3%

Quarter to September 2026, against a year earlier

65.55 0.12 −0.18%
Market cap
$5.5B
P/E
0.0×
Fwd P/E
42.2×
Dividend yield
—
F-score
7/9
Altman Z
1.86
Beneish M
−1.48
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

PTC Therapeutics, Inc. (PTCT) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, PTC Therapeutics, Inc. (PTCT) trades at a EV/Sales of 5.4×. Over the past ten years it has ranged from −1.7× (March 2016) to 89.0× (April 2015); the current reading is higher than 41% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 3.9× (33.77%)
FY2024 5.8× 64.12%
FY2023 3.6× (32.33%)
FY2022 5.3× (12.01%)
FY2021 6.0× (42.21%)
FY2020 10.3× 29.35%
FY2019 8.0× 38.90%
FY2018 5.8× 75.36%
FY2017 3.3× 8.98%
FY2016 3.0× (86.85%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 5.3× (28.31%)
Jun 2026 7.4× (3.66%)
Mar 2026 7.7× 98.30%
Dec 2025 3.9× 24.89%
43 more quarters

Against its own ten years

Low −1.7× High 89.0×
Ten-year median 5.9×
Current reading's percentile 44

EV/Sales against peers

Company EV/Sales
BLTE Belite Bio, Inc. Sponsored ADR compare n/m
MANE Veradermics Incorporated compare n/m
IMVT Immunovant, Inc. compare n/m
KOD Kodiak Sciences Inc. compare n/m
PTCT PTC Therapeutics, Inc. 5.4×
MIRM Mirum Pharmaceuticals, Inc. compare 9.7×
SRRK Scholar Rock Holding Corporation compare 120×
COGT Cogent Biosciences, Inc. compare 195×
CGON CG Oncology, Inc. compare 755×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on PTCT